UK: Is Precision Medicine Hitting The Target?

Last Updated: 20 September 2016
Article by Amen Sanghera

Most Read Contributor in UK, August 2017

I am delighted to use this week's blog to introduce one of the Centre's new analysts, Amen Sanghera. During his MSc studies in Nanotechnology and Regenerative Medicine (2013 -14) Amen was fortunate to gain first-hand exposure to the potential that precision medicine (PM) can have for patients. His blog explores this potential and considers the extent to which key stakeholders (payers, providers, physicians and patients) are ready to embrace the move towards precision medicine.

What is precision medicine?

PM is an emerging approach for treatment and prevention that takes into account a person's genetics, environment and lifestyle. It allows doctors and researchers to predict more accurately which strategies for a particular disease will work in which groups of people. It is in contrast to the traditional "one-size-fits-all" approach in which disease treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.

While the term PM is relatively new, the concept has been around for many years. However, it is only in recent times that we have seen the first tentative steps towards turning the PM rhetoric into reality. Genetic profiling and accompanying diagnostic testing currently form the fundamental driving force in bringing precision therapies to clinical practice. These breakthroughs have allowed providers and physicians to understand diseases at a molecular level and specify a means for accurate diagnosis and the development of targeted therapies.

How has the industry's perspective changed?

PM was initially met with scepticism by the pharmaceutical industry, particularly from a business point of view. The industry saw spending resources developing therapies that treat specific sub-segments of patient populations as reducing the potential size of the addressable market. However, this view has changed over the past decade, thanks to the implementation of favourable regulatory policies and incorporation strategies in major markets. As a result, the percentage of PM drug approvals in the US increased from 22 per cent in 2014 to 29 per cent in 20151 and the number of PM products available on the market increased from 13 in 2006 to 113 in 2014.2

Oncology leading the way

Oncology is one area in which PM is making significant inroads, with the US regulators giving priority to PM for oncology treatment.3 Indeed, in 2015, 36 per cent of newly approved oncology drugs were PMs.4 The increased use of PM in oncology is partly due to being able to demonstrate its clinical advantages more readily in cancer treatment compared to other therapy areas, such as autoimmune diseases.

Slow adoption

Clinical adoption of PM outside of oncology is slow, due to a number of challenges that have deterred key stakeholders from embracing the prescribing of PM therapies. These include:

  • scientific and technical challenges such as overcoming clinical hurdles (demonstrating efficacy), developing therapies for a wider array of diseases, finding the right biomarkers, and a better comprehension of the benefits of molecular therapies amongst payers
  • economic challenges which include incentive systems that are often slow to adapt to new trends in healthcare and are counterproductive in enabling innovation to succeed
  • regulatory roadblocks that have made the approval process for PM unclear and convoluted, particularly in markets outside of the US such as the UK and Germany
  • operational challenges which includes the need for healthcare infrastructures capabilities and technologies that support the standardised collection and safe storage of data, enable faster diagnostic testing; and the training of medical personnel on understanding diagnosis and precision treatments.

Economic considerations of precision medicine

There are also long term economical concerns on how the business model for PM will play out. Technologies to sequence large amounts of genetic information remain expensive (although reducing). The cost of pharmaceutical research and development is inherently high and potential returns on investment are constrained by the smaller size of the treatable population, leading to high prescribing costs. Furthermore, there is the cost of investment in the capability and capacity to obtain precision diagnostics and deliver personalised treatment when compared to traditional approaches that may not benefit a proportion of the population treated.4 On the other hand PM could lead to a drop in research and development costs as the rates of failure and time taken to prove efficacy reduce, ultimately lowering costs for patients.5 We are at a tipping point where the evidence to underpin the business model is only now emerging. Realising the potential of PM will need to be underpinned by more precise economics.

What will drive change?

In order for these issues to be resolved, a more concerted effort is needed to address the concerns of each of the key stakeholders. Specifically more data is required to understand the clinical and long term economic benefits of PM. As more and more leading institutions begin adopting PM therapies, best practice methodologies should begin to emerge thereby increasing adoption. This in turn should improve patient access to PM at both lower clinical and economical risk than is currently the case.

Healthcare remains an industry in which innovation outpaces regulatory policy, reimbursement processes and clinical reform. PM has only just begun to scratch the surface of its potential. Over the last decade we have seen how the perspective of industry has changed and with the current penetration of PM in oncology, we are seeing key stakeholder views also evolve. Ultimately, it is long term data (clinical and economical) that will help shape the development and adoption of PM. Whether that evidence base is strong enough to promote implementation of PM outside of oncology, only time will tell. However, with the implementation of multiple government backed programmes over the last five years, such as the UK's "100,000 genomes project",6 key enablers for change are now in place.



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.